Updated on 6 March 2013
Other US patent applications by the company of varying scope and specificity are currently pending. These applications are expected to further cement the company's monopoly rights over the entire platform technology.
The patent which has a term through to July 13, 2021, is presently awarded 846 days of patent term adjustment.
"This patent term adjustment may enable ACL to commandeer further potential revenues across 2.3 years resulting from the HA-Irinotecan asset," said Dr West. "Taking into account the patent term adjustment, the patent may expire as late as November 6, 2023, subject to any further adjustments or restrictions by the US Patent & Trade Mark Office."
HyACT technology inventor and ACL Chief Scientific Officer Dr Tracey Brown said the patent claims substantiate HyACT's clinical novelty and provide protection for several HyACT targeted drugs in one of the world's largest oncology markets. "This patent substantially expands the commercial application of our proprietary HyACT technology, and provides Alchemia with the commercial rationale to continue to develop its extensive pipeline of oncology drugs," she added.